225Ac labeled anti-HER2 2Rs15d sdAb as a potential therapeutic for targeted alpha therapy – an in vitro and in vivo evaluation

Research output: Contribution to report/book/conference proceedingsIn-proceedings paperpeer-review

Authors

  • Magdalena Rodak
  • Yana Dekempeneer
  • Maria Wojewodzka
  • Tony Lahoutte
  • Frank Bruchertseifer
  • Alfred Morgenstern
  • Matthias D'Huyvetter
  • Marek Pruszynski
  • Institute of Nuclear Chemistry and Technology
  • VUB - Vrije Universiteit Brussel
  • EC - JRC - European Commission - Joint Research Centre

Documents & links

Abstract

Human epidermal growth factor receptor type 2 (HER2) over expression cause more aggressive form of cancer, metastatic activity and chemo-resistance. Single-domain antibody fragments (sdAbs) are the smallest antibody-derived fragments with beneficial pharmacokinetic properties for molecular imaging and Targeted Radionuclide Therapy (TRT). Therefore, HER2-targeting sdAbs are very attractive vectors for TRT, especially when labeled with .-particle emitters, due to their small size (~15kDa), nM-range affinity, low immunogenicity, rapid clearance from blood and ease of tumor penetration. The goal of this study was to evaluate the therapeutic potential of the anti-HER2 sdAb 2Rs15d labeled with 225Ac

Details

Original languageEnglish
Title of host publicationNuclear Medicine and Biology
PublisherElsevier
PagesS33
Number of pages1
Volume97-97
DOIs
Publication statusPublished - 21 May 2021

Publication series

NameNuclear Medicine and Biology
PublisherElsevier
NumberS33
Volume96-97
ISSN (Electronic)0969-8051

Keywords

  • Radiopharmaceuticals, Therapy, Actinium, Nanobody

ID: 7479539